Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Revenue (2016 - 2025)

Heron Therapeutics' Revenue history spans 12 years, with the latest figure at $40.6 million for Q4 2025.

  • For Q4 2025, Revenue changed 0.47% year-over-year to $40.6 million; the TTM value through Dec 2025 reached $154.9 million, up 7.36%, while the annual FY2025 figure was $154.9 million, 7.36% up from the prior year.
  • Revenue reached $40.6 million in Q4 2025 per HRTX's latest filing, up from $38.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $40.8 million in Q4 2024 to a low of $20.0 million in Q1 2021.
  • Average Revenue over 5 years is $31.0 million, with a median of $31.6 million recorded in 2023.
  • Peak YoY movement for Revenue: dropped 21.19% in 2021, then soared 45.38% in 2022.
  • A 5-year view of Revenue shows it stood at $20.7 million in 2021, then soared by 45.38% to $30.0 million in 2022, then increased by 14.0% to $34.2 million in 2023, then increased by 19.13% to $40.8 million in 2024, then decreased by 0.47% to $40.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Revenue are $40.6 million (Q4 2025), $38.2 million (Q3 2025), and $37.2 million (Q2 2025).